Abstract: The present invention relates to a method for the selective analysis of a subpopulation of cells or organelles based determining the level of at least one cell or organelle marker, via the implementation of an adapted DNA toolbox able to convert the presence of a cell or organelle marker into a signal. This method is particularly useful for selecting cells or organelles having a phenotype of interest, analyzing the proteins of said cells or organelles and/or sequencing the DNA and/or RNA of said cells. The present invention also relates to a kit for implementing the method of selective analysis of cells or organelles as defined above.

Abstract: The present disclosure is related to systems and methods of enzymatic degradation of crystallizable polymers or copolymers and PC/IPM containing crystallizable polymers or copolymers.

Abstract: The present disclosure is related to systems and methods of enzymatic degradation of crystallizable polymers or copolymers and PC/IPM containing crystallizable polymers or copolymers.

Abstract: The present disclosure is related to systems and methods of enzymatic degradation of crystallizable polymers or copolymers and PC/IPM containing crystallizable polymers or copolymers.

Abstract: A humidification system can include a heater base, a humidification chamber, and a breathing circuit. A cartridge can be removably coupled to the heater base. The cartridge can include various sensors, probes, sensor wire connectors, heater wire connectors, and/or other features. The cartridge can include features configured to mate with corresponding features on the humidification chamber and the heater base. The cartridge includes a memory, such as an EEPROM, or other suitable storage device. When the cartridge is installed on the heater base, the memory is electrically connected to a processor and/or memory of the heater base. Various models of cartridges can be produced for use with different humidification chambers, breathing circuits, and/or therapies. A connector can be configured to couple an inspiratory conduit to an outlet port of the humidification chamber. The connector can provide a pneumatic connection to the outlet port and an electrical connection to the cartridge.

Abstract: A blast attenuation device (100, 1100) for a gun tube (10). The blast attenuation device (100, 1100) has a first wall section (102, 1102) which defines a first chamber (104, 1104), which extends from an inlet end (106, 1106) having an inlet aperture (108, 1108) to an outlet end (110, 1100) having an outlet aperture (112, 1112). The blast attenuation device (100, 1100) also has a second wall section (122, 1122) which defines a second chamber (124, 1124), which extends from an inlet end (126, 1126) having an inlet aperture (128, 1128) to an outlet end (130, 1130) having an outlet aperture (132, 1132).

Abstract: A magneto-electrophoretic medium that can be globally and locally addressed and erased. The medium provides a writeable display with no perceivable lag and the ability to write and erase with only minimal power requirements. In particular, the magneto-electrophoretic medium can be erased by providing a subthreshold electric stimulus and supplementing a second non-electric stimulus that disturbs the written state and allows the magneto-electrophoretic particles to return to their original state.

Abstract: A microfluidic device comprising: —a first wall comprising a first substrate on which a plurality of closed patterns is grafted, —a second wall, facing the first wall, comprising a second substrate, —a plurality of nucleic acids grafted either on the first substrate or on the second substrate, wherein each nucleic acid comprises a barcode that encodes the position of the nucleic acid on said first or second substrate, wherein at least the plurality of closed patterns or the second substrate is made of an actuatable hydrogel which is swellable between a retracted state and a swollen state in which the closed patterns and the second substrate come into contact.

Abstract: Method for determining tissue positions using an array, which comprise location sequences, the location sequences bind to the tissue samples via ligands. The tissue section which allows localisation tags to be assigned to areas of the tissue comprising a single or plurality of cells or organelles, e.g. about two to ten cells. By triangulation of the localisation tags it is possible to assign a unique relative position in the tissue per cell or organelle.

Abstract: The invention relates to a microfluidic system comprising: a) a solid support comprising at least a first group of oligonucleotides, i. wherein each oligonucleotide in said group comprises a nucleic acid sequence of a first type, of a second type and/or a further type, ii. wherein said nucleic acid sequence of a first type is a barcode sequence, iii. and oligonucleotides comprising the same barcode sequence are grouped together in a group of oligonucleotides on said solid support, iv. wherein the first and further oligonucleotide groups are spatially separated on said solid support, b) wherein said one or more groups of oligonucleotide groups on said solid support are within separate reservoirs of the microfluidics system, c) wherein the one or more reservoirs are accessible to fluids, cells, chemicals and/or microdroplet by means of channels, and d) wherein each reservoir comprises comprising a group of oligonucleotides on said solid support is also trap for a microfluidic droplet.

Abstract: Aspects of the disclosure provide methods and compositions for determining the identity of an analyte using molecular barcodes and single-molecule directed evolution of target biomolecules (e.g., proteins or aptamers).

Abstract: A method for forming an object includes moving an assembly including an energy source, heating an initial layer of build material (31i, 31s, 31, 3, 50) positioned in a build area via forced convection around the energy source of the assembly, and spreading build material (31) on the build area, thereby depositing a second layer of build material (31i, 31s, 31, 3, 50) over the initial layer of build material (31 i, 31s, 31, 3, 50).

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Abstract: The invention provides a compound of Formula (1) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Abstract: Described herein are compounds of Formula I, wherein the variables are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, diabetes, kidney disease, NASH and heart failure.

Abstract: The invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt for example, a hydrate (e.g. a monohydrate) crystalline form (e.g. Form 2 or Form 3) or an amorphous form; as well as pharmaceutical compositions, and the uses thereof in treating diseases, conditions or disorders modulated by GLP-1R in a mammal, such as a human.

Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.

Abstract: In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.

Abstract: An actuator assembly for distributing build material and depositing binder material in an additive manufacturing apparatus may comprise an upper support and a lower support spaced vertically spaced from one another. A recoat head actuator may be coupled to a recoat head and one of the upper support and the lower support. The recoat head actuator may include a recoat motion axis. The recoat head actuator effects bi-directional movement of the recoat head on the recoat motion axis. A print head actuator may be coupled to a print head and the other of the upper support and the lower support. The print head actuator may include a print motion axis. The print head actuator effects bi-directional movement of the print head on the print motion axis. The recoat motion axis and the print motion axis are parallel to one another and spaced apart from one another in the vertical direction.

Abstract: Additive manufacturing apparatuses, components of additive manufacturing apparatuses, and methods of using such manufacturing apparatuses and components are disclosed. An additive manufacturing apparatus may include a recoat head for distributing build material in a build area, a print head for depositing material in the build area, one or more actuators for moving the recoat head and the print head relative to the build area, and a cleaning station for cleaning the print head.